iarjaccIARJACCIARJACC2709-1880https://doi.org/10.47310/iarjacc.2022.v03i01.015Diagnosing GBS in Ventilated SARS-CoV-2 Patients is FeasibleJosefFinstererWe reviewed with interest the study by Diaz et al [1]. on three cases of Guillain-Barré Syndrome (GBS) associated with SARS-CoV-2 infection, all of whom were treated with intravenous immunoglobulins (IVIG) and showed favorable outcomes despite prolonged ICU stays. While the study contributes valuable insights, it presents several limitations. The diagnostic algorithm for GBS in sedated or ventilated patients should be expanded to include autonomic disturbances, cytokine profiles, and response to ex juvantibus IVIG. Important clinical details are missing, including the duration of intubation, timing of symptom recognition, and rationale for delayed GBS diagnosis in two patients. In one case, critical illness neuropathy and drug-induced neuropathy were not adequately ruled out. CSF analyses lacked SARS-CoV-2 PCR testing, and post-vaccination outcomes were not discussed. Autonomic dysfunction and cranial nerve involvement, especially facial diplegia, require further elaboration given their relevance in neuro-COVID. The use of the term “differential diagnoses” for infectious triggers of GBS is inappropriate and should be revised. Overall, while the study offers meaningful observations, these limitations should be addressed to strengthen its conclusions and clinical utility.